National Medical Products Administration
Chinese regulator; issues the China GMP (Drug Administration Law) requirements.
What this page does not claim
SPEQ curates and cross-references these bodies. It is not affiliated with, accredited by, or endorsed by any of them, and a count of decoded standards is a measure of SPEQ’s coverage, not of a body’s importance.
WHAT NMPA COVERS
The National Medical Products Administration regulates drugs, medical devices, and cosmetics in China under the Drug Administration Law and its implementing regulations. It handles registration, GMP oversight, and post-market supervision, with provincial medical products administrations carrying substantial day-to-day inspection responsibility.
WHAT NMPA PUBLISHES
- 01Chinese Pharmacopoeia (ChP) — the compendial standard for products on the Chinese market
- 02China GMP (the 2010 revision) and its appendices for sterile products, biologics, APIs, and TCM
- 03Registration regulations and Center for Drug Evaluation technical review guidance
- 04Inspection findings and administrative penalty decisions published by NMPA and provincial authorities
- 05ICH guidelines as progressively transposed into the Chinese framework
HOW ITS REQUIREMENTS BITE
GMP compliance is enforced through registration-linked and routine inspection, with provincial authorities conducting much of the routine work and NMPA handling higher-risk and imported-product oversight. The 2019 revision of the Drug Administration Law significantly increased penalties and introduced the marketing authorisation holder system, shifting lifecycle accountability onto the MAH.
What practitioners get wrong
- The MAH system introduced in the 2019 Drug Administration Law reassigned lifecycle accountability — confirm who holds it.
- Chinese Pharmacopoeia methods and limits can differ from USP or Ph. Eur.; harmonisation is partial.
- Provincial authorities do much of the routine inspection, so practice can vary by province.
- ICH adoption is progressive — check whether a given guideline is in force in China before relying on it.
What an inspection under this authority actually probes
WHERE IT SITS INTERNATIONALLY
NMPA joined ICH in 2017, became an ICH Management Committee member in 2018, and has been progressively implementing ICH guidelines — which is steadily narrowing the gap between Chinese and international technical requirements, though transposition is guideline-by-guideline rather than wholesale.
NMPA STANDARDS SPEQ DECODES · 3
DISCIPLINES IN NMPA’S REMIT
NMPA: frequently asked questions
Reference answers on National Medical Products Administration’s mandate, what it publishes, and how its requirements acquire force.
What does China’s NMPA regulate?
The National Medical Products Administration regulates drugs, medical devices, and cosmetics in China under the Drug Administration Law, handling registration, GMP oversight, and post-market supervision. Provincial medical products administrations carry substantial day-to-day inspection responsibility.
When did China join ICH?
NMPA joined ICH in 2017 and became an ICH Management Committee member in 2018. It has been progressively implementing ICH guidelines guideline-by-guideline, which steadily narrows the gap between Chinese and international technical requirements.
What changed in China’s 2019 Drug Administration Law?
The 2019 revision significantly increased penalties and introduced the marketing authorisation holder system, shifting lifecycle accountability onto the MAH — confirm who holds it. The compendial standard is the Chinese Pharmacopoeia, whose methods and limits can differ from USP or Ph. Eur.